Callyope vs Ellipsis Health (2026)
Both listen to a patient's voice for clinical signal rather than for words, which is the most technically ambitious thing anyone in behavioral health AI is attempting. Callyope is building an audio and language foundation model trained specifically on psychiatric data rather than adapting a general model, which is a research position and the only one like it in this index. Ellipsis has already productised the idea, with vocal biomarker technology originating in depression and anxiety detection research and now sold as a care management agent to health plans and risk bearing providers. The gap is maturity against method. Ellipsis is deployable now and its inference is doing work in production. Callyope's approach is the better founded one if the claim ever needs defending, because a model built on psychiatric speech starts from the population it is describing.
- The model is trained specifically on psychiatric audio and language rather than adapted from a general purpose speech model, which is a different technical starting point for a population whose speech carries clinical signal.
- Building a foundation model for psychiatry is a research position rather than a product wrapper, and it is the only one of its kind in this index.
- For a research or specialist psychiatric setting, a model built on the target population is more defensible than one fine tuned onto it.
- It is productised and deployed, with a care management agent sold to health plans and at risk providers rather than a model looking for a workflow.
- The vocal biomarker lineage is published research that has been carried into a commercial product, so the technical claim has a trail behind it.
- For a plan trying to reach members between visits, an agent that conducts the conversation is closer to the outcome than a model that analyses one.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Callyope and Ellipsis Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Callyope | Ellipsis Health |
|---|---|---|
| Primary category | Behavioral Health AI | Patient Voice Agents |
| Founded | 2023 | 2017 |
| Headquarters | Paris, France | San Francisco, California |
| Website | callyope.com | ellipsishealth.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Callyope its top capability grade on AI Centrality and AI Safety and PHI Stewardship. Set against Ellipsis Health, Callyope grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Its thinnest published disclosure sits on Commercial Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Ellipsis Health its top capability grade on AI Centrality. Set against Callyope, Ellipsis Health grades higher on several axes, including AI Governance and Bias Disclosure, EHR and Interoperability Depth and Commercial Transparency. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Callyope or Ellipsis Health?
On the axes where the AI Health Index separates them, Callyope grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture, and Ellipsis Health grades higher on several axes, including AI Governance and Bias Disclosure, EHR and Interoperability Depth and Commercial Transparency. Callyope leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Callyope and Ellipsis Health differ most?
The widest separation the AI Health Index records between Callyope and Ellipsis Health is on AI Safety and PHI Stewardship, where Callyope grades A and Ellipsis Health grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Callyope and Ellipsis Health grade the same?
The AI Health Index grades Callyope and Ellipsis Health the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Callyope and Ellipsis Health not disclosed?
At the last review, at least one of Callyope and Ellipsis Health published thin or absent detail on AI Liability and Recourse and Commercial Transparency. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Remote Monitoring & Chronic Care page.
Vocal biomarker inference is the most consequential claim in this pair and the least externally validated: inferring depression or anxiety from voice is a clinical assertion about a person, and neither vendor publishes independent validation of that inference or performance by language, accent, age or medication status, all of which alter voice. Speech changes caused by antipsychotic and antidepressant medication are a specific confound in this population.
Establish with both whether the system is measuring a clinical state or a medication effect, and what happens to the recording, since psychiatric audio carries protections beyond the general health privacy rule in many jurisdictions.